论文部分内容阅读
目的:探讨新辅助化疗对口腔鳞癌(OSCC)患者生存率和生存质量的影响。方法:132例T3、T4OSCC患者随机分为2组:Ⅰ组(单纯手术)75例:Ⅱ组(新辅助化疗﹢手术)57例,应用SPSS10.0软件统计分析两组5年生存率和用华盛顿大学生存质量问卷评价两组患者的生存质量。结果:①Ⅰ组和Ⅱ组的5年生存率分别为42.8﹪、55.8﹪,两组间有显著性差异(P﹤0.05);新辅助化疗有效者和无效者5年生存率分别为66.5﹪、45.9﹪,两组间有显著性差异(P﹤0.05);Ⅱ组中新辅助化疗无效者和Ⅰ组5年生存率分别为45.9﹪、42.8﹪,两组间无显著性差异(P﹥0.05)。②Ⅱ组生存质量总分显著高于Ⅰ组(P﹤0.05);Ⅱ组中新辅助化疗有效者显著高于无效者(P﹤0.05);Ⅱ组中新辅助化疗无效者与Ⅰ组无显著性差异(P﹥0.05)。结论:有效的新辅助化疗能显著提高OSCC患者的生存率和生存质量。
Objective: To investigate the effect of neoadjuvant chemotherapy on the survival rate and quality of life in patients with oral squamous cell carcinoma (OSCC). Methods: 132 patients with T3 and T4OSCC were randomly divided into two groups: group Ⅰ (operation alone) 75 cases: group Ⅱ (neoadjuvant chemotherapy + operation) 57 cases, using SPSS10.0 software statistical analysis of two groups of 5-year survival rate and The University of Washington Quality of Life Questionnaire assesses the quality of life in both groups. Results: ① The 5-year survival rates of group Ⅰ and group Ⅱ were 42.8% and 55.8% respectively, with significant difference between the two groups (P <0.05). The 5-year survival rates of effective and ineffective neoadjuvant chemotherapy were 66.5% 45.9%, there was a significant difference between the two groups (P <0.05). In group Ⅱ, the 5-year survival rates of patients with ineffective neoadjuvant chemotherapy and group Ⅰ were 45.9% and 42.8% respectively, with no significant difference between the two groups (P> 0.05 ). ②The total score of quality of life in groupⅡwas significantly higher than that in groupⅠ (P0.05); the effective rate of neoadjuvant chemotherapy in groupⅡwas significantly higher than that of ineffective groupⅡ (P0.05); There was no significant difference between groupⅡ and groupⅠ Difference (P> 0.05). Conclusion: Effective neoadjuvant chemotherapy can significantly improve the survival rate and quality of life in patients with OSCC.